National Vaccine
Information Center

Your Health. Your Family. Your Choice.

MedAlerts.org
Search Results

This is VAERS ID 1786707

Government Disclaimer on use of this data

History of Changes from the VAERS Wayback Machine

First Appeared on 10/22/2021

VAERS ID: 1786707
VAERS Form:2
Age:15.0
Sex:Male
Location:Foreign
Vaccinated:2021-09-21
Onset:2021-09-25
Submitted:0000-00-00
Entered:2021-10-15
Vaccin­ation / Manu­facturer Lot / Dose Site / Route
COVID19: COVID19 (COVID19 (MODERNA)) / MODERNA - / 2 - / OT

Administered by: Unknown      Purchased by: ??
Symptoms: Chest discomfort, Chest pain, Myocarditis

Life Threatening? No
Birth Defect? No
Died? No
Permanent Disability? No
Recovered? No
Office Visit (V2.0)? No
ER or Office Visit (V1.0)? No
ER or ED Visit (V2.0)? No
Hospitalized? Yes, days:     Extended hospital stay? No
Previous Vaccinations:
Other Medications:
Current Illness:
Preexisting Conditions: Medical History/Concurrent Conditions: Protein C increased; Troponin I increased
Allergies:
Diagnostic Lab Data:
CDC 'Split Type': ITMODERNATX, INC.MOD20213

Write-up: Sep 21, 2nd dose of the Moderna Covid-19 vaccine; Sep 25, chest tightness and pain, troponin I elevation up to 4561 ng/L and CRP, waiting to perform cardiac MRI, suspected myocarditis; 21/9 2a dose Covid19 Moderna, 25/9, a 4561 ng/L e PCR, chest tightness; This regulatory authority case was reported by a physician and describes the occurrence of MYOCARDITIS (Sep 21, 2nd dose of the Moderna Covid-19 vaccine; Sep 25, chest tightness and pain, troponin I elevation up to 4561 ng/L and CRP, waiting to perform cardiac MRI, suspected myocarditis) and CHEST PAIN (21/9 2a dose Covid19 Moderna, 25/9 a 4561 ng/L e PCR, in a 15-year-old male patient who received mRNA-1273 (Spikevax) for COVID-19 immunisation. The occurrence of additional non-serious events is detailed below. Concurrent medical conditions included Troponin I increased on 25-Sep-2021 and Protein C increased on 25-Sep-2021. On 21-Sep-2021, the patient received second dose of mRNA-1273 (Spikevax) (Intramuscular) 1 dosage form. On 25-Sep-2021, the patient experienced MYOCARDITIS (Sep 21, 2nd dose of the Moderna Covid-19 vaccine; Sep 25, chest tightness and pain, troponin I elevation up to 4561 ng/L and CRP, waiting to perform cardiac MRI, suspected myocarditis) (seriousness criteria hospitalization and medically significant), CHEST PAIN (21/9 2a dose Covid19 Moderna, 25/9 a 4561 ng/L e PCR, (seriousness criterion hospitalization) and CHEST DISCOMFORT (chest tightness). At the time of the report, MYOCARDITIS (Sep 21, 2nd dose of the Moderna Covid-19 vaccine; Sep 25, chest tightness and pain, troponin I elevation up to 4561 ng/L and CRP, waiting to perform cardiac MRI, suspected myocarditis), CHEST PAIN (21/9 2a dose Covid19 Moderna, 25/9 a 4561 ng/L e PCR, and CHEST DISCOMFORT (chest tightness) was resolving. For mRNA-1273 (Spikevax) (Intramuscular), the reporter did not provide any causality assessments. On 25-SEP-2021 the patient had an Echocardiogram and Troponin I done, Troponin was elevated to 4561 ng/L and CRP was done. Patient was waiting to perform Cardiac MRI which resulted in myocarditis. Patient was suspected to myocarditis with a peak TNL 4500 ng/ml and chest pain in remission and TNL declining and after few days of second vaccination patient had preserved cardiac function and was awaiting for Cardiac MRI. Concomitant medications and treatment information was not provided. Patient had took the second dose on 21-SEP-2021 and on 25-SEP-2021 experienced chest tightness and pain. Lab data: On unknown date Echocardiogram was done with unknown results. On 25 Sep 2021: MRI, Troponin I, Blood test was done with unknown results. Most recent FOLLOW-UP information incorporated above includes: On 08-Oct-2021: Translation received on 12-OCT-2021 contains: Event Verbatim Updated and Reporter''s comment updated in narrative. On 12-Oct-2021: Significant follow up received lab data and events were added.; Sender''s Comments: This case concerns a 15-year-old male patient with no relevant medical history, who experienced the unexpected serious AESI event of Myocarditis with unexpected serious event of Chest pain. The events occurred approximately 5 days after the second dose of Spikevax administration. The rechallenge was not applicable since no events were reported after the first dose and no additional dosing was expected. The benefit-risk relationship is not affected by this report. The event Myocarditis was assessed as UNEXPECTED per current guidance, since it occurred in a 15-year-old patient.

New Search

Link To This Search Result:

https://medalerts.org/vaersdb/findfield.php?IDNUMBER=1786707&WAYBACKHISTORY=ON


Copyright © 2022 National Vaccine Information Center. All rights reserved.
21525 Ridgetop Circle, Suite 100, Sterling, VA 20166